Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 4 de 4
Filtrer
Plus de filtres











Base de données
Gamme d'année
1.
Eur J Med Chem ; 277: 116760, 2024 Nov 05.
Article de Anglais | MEDLINE | ID: mdl-39197252

RÉSUMÉ

Acute lung injury (ALI) is a severe respiratory disorder closely associated with the excessive activation of the NLRP3 inflammasome. Oridonin (Ori), a natural diterpenoid compound, had been confirmed as a specific covalent NLRP3 inflammasome inhibitor, which was completely different from that of MCC950. However, the further clinical application of Ori was limited by its weak inhibitory activity against NLRP3 inflammasome (IC50 = 1240.67 nM). Fortunately, through systematic structure-optimization of Ori, D6 demonstrated the enhancement of IL-1ß inhibitory activity (IC50 = 41.79 nM), which was better than the parent compound Ori. Then, by using SPR, molecular docking and MD simulation, D6 was verified to directly interact with NLRP3 via covalent and non-covalent interaction. The further anti-inflammatory mechanism studies were revealed that D6 could inhibit the activation of NLRP3 inflammasome without affecting the initiation phase of NLRP3 inflammasome activation, and D6 was a broad-spectrum and selective NLRP3 inflammasome inhibitor. Finally, D6 demonstrated a favorable therapeutic effect on LPS-induced ALI in mice model, and the potent pharmacodynamic effect of D6 was correlated with the specific inhibition of NLRP3 inflammasome activation in vivo. Thus, D6 is proved as a potent NLRP3 inhibitor, and has the potential to develop as a novel anti-ALI agent.


Sujet(s)
Lésion pulmonaire aigüe , Diterpènes de type kaurane , Conception de médicament , Inflammasomes , Protéine-3 de la famille des NLR contenant un domaine pyrine , Lésion pulmonaire aigüe/traitement médicamenteux , Lésion pulmonaire aigüe/métabolisme , Diterpènes de type kaurane/pharmacologie , Diterpènes de type kaurane/synthèse chimique , Diterpènes de type kaurane/composition chimique , Protéine-3 de la famille des NLR contenant un domaine pyrine/antagonistes et inhibiteurs , Protéine-3 de la famille des NLR contenant un domaine pyrine/métabolisme , Animaux , Inflammasomes/antagonistes et inhibiteurs , Inflammasomes/métabolisme , Souris , Relation structure-activité , Structure moléculaire , Humains , Relation dose-effet des médicaments , Lipopolysaccharides/pharmacologie , Lipopolysaccharides/antagonistes et inhibiteurs , Mâle , Souris de lignée C57BL , Simulation de docking moléculaire
2.
Eur J Med Chem ; 272: 116426, 2024 Jun 05.
Article de Anglais | MEDLINE | ID: mdl-38718622

RÉSUMÉ

Pyruvate kinase isoform 2 (PKM2) is closely related to the regulation of Th17/Treg balance, which is considered to be an effective strategy for UC therapy. Parthenolide (PTL), a natural product, only possesses moderate PKM2-activating activity. Thus, five series of PTL derivatives are designed and synthesized to improve PKM2-activated activities and anti-UC abilities. Through detailed structure optimization, B4 demonstrates potent T-cell anti-proliferation activity (IC50 = 0.43 µM) and excellent PKM2-activated ability (AC50 = 0.144 µM). Subsequently, through mass spectrometry analysis, B4 is identified to interact with Cys423 of PKM2 via covalent-bond. Molecular docking and molecular dynamic simulation results reveal that the trifluoromethoxy of B4 forms a stronger hydrophobic interaction with Ala401, Pro402, and Ile403. In addition, B4 has a significant effect only on Th17 cell differentiation, thereby regulating the Th17/Treg balance. The effect of B4 on Th17/Treg imbalance can be attributed to inhibition of PKM2 dimer translocation and suppression of glucose metabolism. Finally, B4 can notably ameliorate the symptoms of dextran sulfate sodium (DSS)-induced colitis in mouse model in vivo. Thus, B4 is confirmed as a potent PKM2 activator, and has the potential to develop as a novel anti-UC agent.


Sujet(s)
Rectocolite hémorragique , Conception de médicament , Lactones , Pyruvate kinase , Sesquiterpènes , Sesquiterpènes/pharmacologie , Sesquiterpènes/composition chimique , Sesquiterpènes/synthèse chimique , Animaux , Souris , Pyruvate kinase/métabolisme , Pyruvate kinase/antagonistes et inhibiteurs , Lactones/pharmacologie , Lactones/composition chimique , Lactones/synthèse chimique , Relation structure-activité , Rectocolite hémorragique/traitement médicamenteux , Rectocolite hémorragique/induit chimiquement , Humains , Structure moléculaire , Prolifération cellulaire/effets des médicaments et des substances chimiques , Souris de lignée C57BL , Relation dose-effet des médicaments , Mâle , Sulfate dextran , Simulation de docking moléculaire , Hormones thyroïdiennes/métabolisme , Cellules Th17/effets des médicaments et des substances chimiques ,
3.
J Med Chem ; 66(8): 5500-5523, 2023 04 27.
Article de Anglais | MEDLINE | ID: mdl-37017305

RÉSUMÉ

The pyruvate kinase M2 (PKM2) can significantly affect the differentiation of Th17 and Treg cells; thus, it is considered a promising target for UC therapy. Herein, five series of costunolide (Cos) derivatives are designed, synthesized, and biologically evaluated. Among them, D5 exhibits excellent immunomodulatory activity against T-cell proliferation and potent PKM2 activating activity. Meanwhile, it has been confirmed that D5 can also covalently interact with Cys424 of PKM2. The molecular docking and molecular dynamic (MD) studies indicate that difluorocyclopropyl derivative of D5 improves the protein-ligand interaction by interacting with Arg399 electrostatically. Furthermore, D5 significantly dampens the differentiation of Th17 but not Treg cells to recover the Th17/Treg balance, which is attributed to the suppression of PKM2-mediated glycolysis. Oral administration of D5 ameliorates the symptoms of dextran sulfate sodium (DSS)- and 2,4,6-trinitro-benzenesulfonic acid (TNBS)-induced colitis in mouse model. Collectively, D5 has the potential to be developed as a novel anti-UC candidate.


Sujet(s)
Rectocolite hémorragique , Colite , Animaux , Souris , Colite/induit chimiquement , Simulation de docking moléculaire
4.
J Agric Food Chem ; 59(10): 5376-81, 2011 May 25.
Article de Anglais | MEDLINE | ID: mdl-21452895

RÉSUMÉ

Cellulose acetate butyrate (CAB) and cellulose acetate propionate (CAP) were prepared homogeneously in a 1-allyl-3-methylimidazolium chloride (AmimCl) ionic liquid system from sugarcane bagasse (SB). The reaction temperature, reaction time, and molar ratio of butyric (propionic) anhydride/anhydroglucose units in the cellulose affect the butyryl (B) or propionyl (P) content of CAB or CAP samples. The (13)C NMR data revealed the distribution of the substituents of CAB and CAP. The thermal stability of sugar cane bagasse cellulose was found by thermogravimetric analysis to have decreased after chemical modification. After reaction, the ionic liquid was effectively recycled and reused. This study provides a new way for high-value-added utilization of SB and realizing the objective of turning waste into wealth.


Sujet(s)
Cellulose/analogues et dérivés , Cellulose/synthèse chimique , Cellulose/composition chimique , Stabilité de médicament , Déchets industriels , Liquides ioniques/composition chimique , Spectroscopie par résonance magnétique , Recyclage , Saccharum/composition chimique , Température
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE